BIOLOGICAL MARKERS PREDICTIVE OF RHEUMATOID ARTHRITIS RESPONSE TO LYMPHOTOXIN ANTAGONISTS
摘要
<p>The present invention relates to a soluble lymphotoxin (solLT) and methods of using the solLT as a biomarker in the treatment of autoimmune disease. More particularly, the present invention relates to soluble lymphotoxin alpha-beta (solLTaß) and methods of using this solLTaß as a biomarker in the treatment of rheumatoid arthritis (RA).</p>
